Huntington’s Disease
CLINICAL TRIALS FOR PARKINSON’S DISEASE
To inquire about your eligibility to enroll in one of our clinical trials, please email neuro.cognitive.research@uth.tmc.edu or call our clinic’s front office at 713-486-0500 and ask to speak to a research coordinator.
Collaborative Studies with Pharmaceutical Companies
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease (KINECT-HD)
The purpose of this study is to evaluate the effectiveness of valbenazine to reduce chorea associated with Huntington’s Disease
- Patients with chorea associated with Huntington’s Disease
- Sponsored by Neurocrine Biosciences Inc.
- Age: 18-75 years
- Study will last for approximately 18 weeks
Principal Investigator: Dr. David Hunter